Embecta Corp., (EMBC) News

Embecta Corp., (EMBC): $10.88

0.16 (+1.49%)

POWR Rating

Component Grades








Filter EMBC News Items

EMBC News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

EMBC News Highlights

  • For EMBC, its 30 day story count is now at 3.
  • Over the past 7 days, the trend for EMBC's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about EMBC are DEC.

Latest EMBC News From Around the Web

Below are the latest news stories about EMBECTA CORP that investors may wish to consider to help them evaluate EMBC as an investment opportunity.

Zacks Investment Ideas feature highlights: Beacon Roofing Supply, Embecta and Western Midstream Partners

Beacon Roofing Supply, Embecta and Western Midstream Partners have been highlighted in this Investment Ideas article.

Yahoo | December 21, 2023

Time to Buy These Intriguing Additions to Zacks Rank #1 (Strong Buy) List

Several intriguing stocks were recently added to the Zacks Rank #1 (Strong Buy) list this week and shouldn't be overlooked as we round out what has been an exciting year for the stock market.

Yahoo | December 20, 2023

embecta to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

PARSIPPANY, N.J., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that management will present at the J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2024 at 2:15 p.m. PT / 5:15 p.m. ET. Audio webcasts of the presentations will be accessible under the “News & Events” section of the Company's investor relations website at investors.embecta.com. About embecta embecta is a global diabetes care company that is leveraging its nearl

Yahoo | December 14, 2023

No embecta-made syringes impacted by FDA safety communication

PARSIPPANY, N.J., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company, today issued the following statement regarding the U.S. Food and Drug Administration (FDA) Safety Communication on evaluation of certain plastic syringes: “embecta, the world’s largest manufacturer of plastic insulin syringes, manufactures all of our syringes distributed worldwide at our facility in Holdrege, Nebraska,” said Shaun Curtis, SVP, Global Manufacturing & Suppl

Yahoo | December 1, 2023

Embecta Corp's Dividend Analysis

Embecta Corp(NASDAQ:EMBC) recently announced a dividend of $0.15 per share, payable on 2023-12-15, with the ex-dividend date set for 2023-12-01. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using the data from GuruFocus, let's look into Embecta Corps dividend performance and assess its sustainability.

Yahoo | December 1, 2023

embecta to Participate in Investor Conferences

PARSIPPANY, N.J., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company, today announced that management will participate in the following investor events: 2023 Mizuho Medical Device and Healthcare Services Summit Management will host one-on-one investor meetings on Wednesday, December 6, 2023, at Sofitel Hotel, New York. 2023 MedTech Madness Annual West Coast Bus Tour Management will host a fireside session on Monday, December 11, 2023, at 9:

Yahoo | November 29, 2023

Should Income Investors Look At Embecta Corp. (NASDAQ:EMBC) Before Its Ex-Dividend?

Embecta Corp. ( NASDAQ:EMBC ) is about to trade ex-dividend in the next 4 days. The ex-dividend date is one business...

Yahoo | November 26, 2023

Embecta Corp. (NASDAQ:EMBC) Q4 2023 Earnings Call Transcript

Embecta Corp. (NASDAQ:EMBC) Q4 2023 Earnings Call Transcript November 21, 2023 Embecta Corp. beats earnings expectations. Reported EPS is $0.59, expectations were $0.42. Operator: Welcome, ladies and gentlemen, to the Fiscal Fourth Quarter and Full Year 2023 embecta Earnings Conference Call. at this time, all participants have been placed in a listen-only mode. Please note […]

Yahoo | November 22, 2023

Embecta CEO Dev Kurdikar talks about growth expectations, GLP-1s

The CEO said the company’s growth expectations have not changed in the near term, even with the rise of weight loss drugs.

Yahoo | November 21, 2023

Embecta Corp. (EMBC) Beats Q4 Earnings and Revenue Estimates

Embecta Corp. (EMBC) delivered earnings and revenue surprises of 40.48% and 1.75%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 21, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!